



BioNova to Present Preclinical Data of BN104 at 2022 American Association for Cancer Research (AACR) Annual Meeting

SHANGHAI, China, April. 11, 2022 - BioNova Pharmaceuticals Limited (BioNova), a company dedicated to the discovery, development and commercialization of innovative medicines for the treatment of diseases with unmet medical needs, will present a poster for preclinical data of BN104 (BNM-1192) from its internal discovery portfolio at the upcoming Annual Meeting of 2022 American Association for Cancer Research (AACR) in New Orleans on April 8-13, 2022.

Poster Presentation Details

Abstract #3943: Discovery of A Novel Menin-MLL Inhibitor for Potential Treatment of MLLr Leukemias and NPM1c AML

Date/Time: Wednesday, April 13, 2022, 9:00 AM- 12:30 PM

Session Title: Emerging New Anticancer Agents

Location: Poster Section 22

“We are excited to present our in-house research work of BN104 at AACR, which has demonstrated best-in-class potential in our preclinical head-to-head research studies.” said Ye Hua, M.D., Founder and CEO of BioNova, “Our internal discovery is a valuable engine that drives BioNova innovative pipeline. We remain committed to cutting-edge drug discovery and research to deliver novel therapies to patients with unmet medical needs.”

BN104 is a novel, potent and highly selective small molecule menin inhibitor for potential treatment of acute leukemias with rearranged mixed lineage leukemia (MLLr) gene. It showed optimized drug-like properties and excellent efficacy in MV4-11 xenograft mouse model. Furthermore, BN104 has low risk in corrected QT interval (QTc) prolongation given the fact that it is an extremely weak human ether-a-go-go related gene (hERG) inhibitor with IC50 of greater than 100 μ M. To date, BN104 has demonstrated favorable toxicity profile in preliminary preclinical studies.

About BioNova

BioNova Pharmaceuticals Limited is a privately held clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative medicines for cancer and other life-threatening diseases with high unmet medical needs. Headquartered in Shanghai, BioNova is a fast-growing company of which robust pipeline is built upon internal R&D programs, collaborations with and acquisitions from partners of cutting-edge technology. With a highly capable and experienced team in combination with substantial funding, BioNova is committed to delivering high-quality innovative medicines to patients in China and globally.

For further information, please refer to <https://www.bionovapharma.com>.

Contact BioNova

Claire Shan

IR & PR Manager

Email: claire.shan@bionovapharma.com

Tel: +86 (21) 5090 1280